Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2– patients with metastatic breast cancer

Palbociclib has shown satisfactory outcomes when combined with endocrine therapy (ET) in hormone receptor–positive and human epidermal growth factor receptor 2–negative (HR+/HER2–) metastatic breast cancer (MBC). However, data in Asia are currently scarce.This retrospective study aimed to evaluate t...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jingping, Zhang, Xiangmei, Yang, Chao, Lv, Yalei, Yang, Hua, Kong, Xiangshun, Han, Meng, Wang, Zunyi, Ma, Jie, Han, Jianjun, Liu, Yunjiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5750
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8568379/
https://www.ncbi.nlm.nih.gov/pubmed/34871262
http://dx.doi.org/10.1097/MD.0000000000027710

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8568379/
https://www.ncbi.nlm.nih.gov/pubmed/34871262
http://dx.doi.org/10.1097/MD.0000000000027710

Ejemplares similares